Contact this trialFirst, we need to learn more about you.
Radiation
Xevinapant + Radiotherapy for Head and Neck Cancer
Recruiting1 awardPhase 3
Marietta, Georgia
This trial tests Xevinapant combined with radiotherapy for high-risk head and neck cancer patients who can't use standard treatment. The drug aims to make cancer cells more sensitive to radiation, improving treatment effectiveness. Xevinapant is a newer drug being tested to enhance the sensitivity of cancer cells to radiation in high-risk head and neck cancer patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service